Reporte zur Charge LH7HN5

Symptomtext

Exposure to AREXVY during pregnancy; 36 years old patient received Arexvy vaccine; This non-serious prospective pregnancy case was reported by a physician via call center representative and described the occurrence of vaccine exposure during pregnancy in a 36-year-old female patient who received RSVPreF3 adjuvanted (Arexvy) (batch number X723B, expiry date 08-DEC-2024) for prophylaxis. On 29-SEP-2023, the patient received Arexvy (left arm). On 29-SEP-2023, an unknown time after receiving Arexvy, the patient experienced inappropriate age at vaccine administration (Verbatim: 36 years old patient received Arexvy vaccine). On an unknown date, the patient experienced vaccine exposure during pregnancy (Verbatim: Exposure to AREXVY during pregnancy). The outcome of the vaccine exposure during pregnancy and inappropriate age at vaccine administration were unknown. Pregnancy exposure: Pregnancy Exposure (Arexvy): Trimester unknown Pregnancy Outcome: Pregnancy was ongoing Additional Information: GSK Receipt Date: 13-Nov-2023 The reporter reported that the pregnant woman patient received Arexvy vaccine, which led to vaccine exposure during pregnancy. The patient received Arexvy who was younger than the indicated age which led to inappropriate age at vaccine administration. The reporter did consent to follow up.